{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pulmonary+Tuberculosis",
    "query": {
      "condition": "Pulmonary Tuberculosis"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 49,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pulmonary+Tuberculosis&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-27T00:19:18.350Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04884308",
      "title": "Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis",
        "Bronchiectasis Adult",
        "Non-Tuberculous Mycobacteria"
      ],
      "interventions": [
        {
          "name": "BCG TICE Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-04-28",
      "completion_date": "2023-12-30",
      "has_results": true,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-06-27T00:19:18.350Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04884308"
    },
    {
      "nct_id": "NCT02252198",
      "title": "Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Epistem Genedrive® and MolBio Truenat™",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 504,
      "start_date": "2014-02",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2017-12-12",
      "last_synced_at": "2026-06-27T00:19:18.350Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02252198"
    },
    {
      "nct_id": "NCT03199339",
      "title": "A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis",
        "Tuberculosis, Pulmonary"
      ],
      "interventions": [
        {
          "name": "TBA-7371",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Global Alliance for TB Drug Development",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "19 Years to 50 Years"
      },
      "enrollment_count": 74,
      "start_date": "2017-08-29",
      "completion_date": "2018-07-08",
      "has_results": false,
      "last_update_posted_date": "2018-10-17",
      "last_synced_at": "2026-06-27T00:19:18.350Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03199339"
    },
    {
      "nct_id": "NCT00468104",
      "title": "Efficacy and Safety of Activase (Ateplase) vs Placebo in Complicated Pleural Effusions (CPE)/Empyemas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pleural Effusion Associated With Pulmonary Infection",
        "Bacterial Pleural Effusion Other Than Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Alteplase",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Midwest Pulmonary and Critical Care",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2004-04",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2012-04-30",
      "last_synced_at": "2026-06-27T00:19:18.350Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00468104"
    },
    {
      "nct_id": "NCT04865536",
      "title": "Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis",
        "Tuberculosis, Pulmonary"
      ],
      "interventions": [
        {
          "name": "TBI-223 1800 mg",
          "type": "DRUG"
        },
        {
          "name": "TBI-223 2400mg",
          "type": "DRUG"
        },
        {
          "name": "TBI-223 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Global Alliance for TB Drug Development",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "19 Years to 50 Years"
      },
      "enrollment_count": 28,
      "start_date": "2021-02-03",
      "completion_date": "2022-05-17",
      "has_results": false,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-06-27T00:19:18.350Z",
      "location_count": 1,
      "location_summary": "Fair Lawn, New Jersey",
      "locations": [
        {
          "city": "Fair Lawn",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04865536"
    },
    {
      "nct_id": "NCT04553406",
      "title": "Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mycobacterium Avium Complex",
        "Non-tuberculous Mycobacterium Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "SPR720",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Open-label Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spero Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2020-12-03",
      "completion_date": "2021-01-28",
      "has_results": true,
      "last_update_posted_date": "2022-02-28",
      "last_synced_at": "2026-06-27T00:19:18.350Z",
      "location_count": 9,
      "location_summary": "Altamonte Springs, Florida • Atlantis, Florida • Clearwater, Florida + 6 more",
      "locations": [
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        },
        {
          "city": "Atlantis",
          "state": "Florida"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04553406"
    },
    {
      "nct_id": "NCT00000796",
      "title": "A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections",
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Cycloserine",
          "type": "DRUG"
        },
        {
          "name": "Ethionamide",
          "type": "DRUG"
        },
        {
          "name": "Capreomycin sulfate",
          "type": "DRUG"
        },
        {
          "name": "Aminosalicylic acid",
          "type": "DRUG"
        },
        {
          "name": "Streptomycin sulfate",
          "type": "DRUG"
        },
        {
          "name": "Ethambutol hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Amikacin sulfate",
          "type": "DRUG"
        },
        {
          "name": "Isoniazid",
          "type": "DRUG"
        },
        {
          "name": "Pyrazinamide",
          "type": "DRUG"
        },
        {
          "name": "Pyridoxine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Levofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "Clofazimine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 525,
      "start_date": null,
      "completion_date": "1998-10",
      "has_results": false,
      "last_update_posted_date": "2021-11-03",
      "last_synced_at": "2026-06-27T00:19:18.350Z",
      "location_count": 21,
      "location_summary": "Chicago, Illinois • Detroit, Michigan • Brooklyn, New York + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000796"
    },
    {
      "nct_id": "NCT02410772",
      "title": "TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "rifapentine",
          "type": "DRUG"
        },
        {
          "name": "rifapentine and moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 2516,
      "start_date": "2016-01-25",
      "completion_date": "2021-05",
      "has_results": true,
      "last_update_posted_date": "2024-12-04",
      "last_synced_at": "2026-06-27T00:19:18.350Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • New York, New York • Fort Worth, Texas + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02410772"
    },
    {
      "nct_id": "NCT04493671",
      "title": "Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pulmonary Disease",
        "Tuberculosis, Pulmonary",
        "Tuberculosis",
        "Multi Drug Resistant Tuberculosis",
        "Drug Sensitive Tuberculosis",
        "Drug-resistant Tuberculosis",
        "Mycobacterium Tuberculosis Infection"
      ],
      "interventions": [
        {
          "name": "TBAJ-876 suspension",
          "type": "DRUG"
        },
        {
          "name": "Placebo suspension",
          "type": "DRUG"
        },
        {
          "name": "TBAJ-876 100 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "TBAJ-876 25 mg tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Global Alliance for TB Drug Development",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "19 Years to 50 Years"
      },
      "enrollment_count": 137,
      "start_date": "2020-06-08",
      "completion_date": "2022-11-15",
      "has_results": false,
      "last_update_posted_date": "2025-06-04",
      "last_synced_at": "2026-06-27T00:19:18.350Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04493671"
    },
    {
      "nct_id": "NCT00694629",
      "title": "TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Tuberculosis"
      ],
      "interventions": [
        {
          "name": "rifampin",
          "type": "DRUG"
        },
        {
          "name": "rifapentine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 865,
      "start_date": "2008-12",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2014-05-08",
      "last_synced_at": "2026-06-27T00:19:18.350Z",
      "location_count": 23,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00694629"
    }
  ]
}